Liver fibrosis Digestive System Hepatic fibrosis
Conditions
Interventions
Participants will be recruited largely from rheumatology and dermatology outpatient clinics in York and Scarborough Hospitals. Over the 12 month study period we will aim to recruit 698 patients. Contr
including blood test results, duration and cumulative dose of MTX prescribed (if relevant), patient demographic data such as postcode, age and gender. The data will be recorded in an EXCEL file, with
they will be given adequate time and assisted for any special needs as appropriate. The questionnaire focusses on patients' understanding and knowledge of methotrexate. The answers are in both qualita
Sponsors
York Teaching Hospital NHS Foundation Trust
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Individuals in the methotrexate cohort must have taken this medication for at least 6 months 2. All participants must be over 18 years old
Exclusion criteria
Exclusion criteria: 1. Pregnant females 2. Previously taken methotrexate, but are no longer currently taking it 3. Lack capacity to consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Presence of liver fibrosis (by liver Fibroscan®) | — |
Secondary
| Measure | Time frame |
|---|---|
| Risk factors for liver fibrosis will be assessed for each participant e.g. presence of diabetes mellitus, BMI and body mass composition, current and previous alcohol use, cumulative dose and duration of methotrexate use etc. | — |
Countries
United Kingdom
Outcome results
None listed